Pharma Focus Asia

Archer, Inc Launches Next-Generation Sequencing (NGS) Device to Identify NTRK Gene Fusions in Cancer

ArcherDX, Inc has discovered a new next-generation sequencing (NGS) device to detect Neurotrophic Receptor Tyrosine Kinase (NTRK) gene fusions that leads to the formation and growth of cancer.

The role of Companion Diagnostic (CDx) is to indicate Neurotrophic Receptor Tyrosine Kinase (NTRK) gene fusions, thus helping to prevent the growth of cancers.

Usually  it’s very tough to detect NTRK gene fusions in cancers, hence with the help of newly designed next-generation sequencing technology which makes use of RNA to provide sensitive NTRK fusion detection makes easier without requiring prior knowledge of fusion partners for any solid tumour.

The newly developed NGS technology makes use of advanced Anchored Multiplex PCR (AMP) chemistry which captures DNA, RNA or ctDNA from both blood and tissue samples irrespective of the location of the tumour.

This breakthrough technology allows diagnostics for patients in community and regional settings where  there  is shortage of  infrastructure and expertise to implement sophisticated genomic analysis.

ArcherDX recently announced a collaboration to develop an NGS-based CDx for a TRK inhibitor.

Next-generation sequencing (NGS) device also received the U.S. Food and Drug Administration’s (FDA’s) breakthrough device designation.

magazine-slider-imageCytiva - Supor Prime filtersMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024